论文部分内容阅读
目的对肝炎肝硬化并发上消化道出血的患者采用奥曲肽治疗并对可行性进行研究。方法选取肝炎肝硬化并发上消化道出血的患者240例作为本次研究对象,采用随机数字分配法分成对照组和奥曲肽组各120例。对照组患者治疗用药为常规使用的垂体后叶素,奥曲肽组患者治疗用药为奥曲肽,对2组患者治疗的成功率,止血时间以及发生不良反应的概率进行比较分析。结果奥曲肽组患者治疗成功率为96.67%(116/120),对照组患者治疗成功率为84.17%(101/120);奥曲肽组患者的止血时间为(19.6±9.8)h,对照组患者的止血时间为(33.4±11.2)h;奥曲肽组患者不良反应的发生率为5.83%(7/120),对照组患者不良反应的发生率为17.50%(21/120)。结论结果显示,2组奥曲肽的临床治疗效果更佳,具有迅速止血,不良反应少的优势。
Objective To investigate the feasibility of octreotide treatment in patients with hepatitis and cirrhosis complicated with upper gastrointestinal bleeding. Methods A total of 240 patients with hepatitis and cirrhosis complicated by upper gastrointestinal hemorrhage were selected as the study subjects and randomly divided into control group and octreotide group (120 cases). Patients in the control group were treated with pituitrin, octreotide was used routinely, and octreotide was used in the patients treated with octreotide. The success rate, hemostasis time and the probability of adverse reactions in the two groups were compared. Results The success rate of treatment was 96.67% (116/120) in octreotide group and 84.17% (101/120) in control group. The bleeding time in octreotide group was (19.6 ± 9.8) h, and the control group (33.4 ± 11.2) h. The incidence of adverse reactions in octreotide group was 5.83% (7/120). The incidence of adverse reactions in control group was 17.50% (21/120). Conclusion The results showed that the two groups of octreotide clinical treatment better, with rapid bleeding, adverse reactions less advantages.